Search

Displaying results 3231 - 3240 of 10000 in total
  1. Drug

    Suzetrigine

    go.drugbank.com/drugs/DB18927
    ApprovedInvestigational

    signal transmission, making it a desirable therapeutic target for treatment of pain. … [A264953] On January 30, 2025, suzetrigine was approved by the FDA as a first-in-class non-opioid analgesic.[L52098]

  2. Drug

    DPI-221

    go.drugbank.com/drugs/DB06121
    Experimental

    DPI-221 is an investigational drug and a selective agonist for the δ-opioid receptor.

  3. Drug

    4-Hydroxytestosterone

    go.drugbank.com/drugs/DB01485
    IllicitInvestigational

    It is an anabolic steroid with no therapeutic indications, which is prohibited from use in sports by the World Anti-Doping Agency. … Formestane (Lentaron) acts as a prohormone of 4-Hydroxytestosterone, as 4-Hydroxytestosterone is one of the many byproducts of formestane metabolism.

  4. Drug

    SPP 301

    go.drugbank.com/drugs/DB05290
    Investigational

    SPP301 (Avosentan) is a potent and highly selective ET[A] receptor blocker and is clinically investigated in diabetic nephropathy. … This study was designed to evaluate whether avosentan influences the pharmacokinetics of steroid oral contraceptives.

  5. Drug

    Palladium Pd-103

    go.drugbank.com/drugs/DB15016
    Experimental

    Palladium Pd-103 is under investigation in clinical trial NCT00247312 (Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial).

  6. Drug

    Lumefantrine

    go.drugbank.com/drugs/DB06708
    ApprovedInvestigational

    Lumefantrine is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with artemether for improved efficacy. … This combination therapy exerts its effects against the erythrocytic stages of <i>Plasmodium spp.

  7. Drug

    Fosphenytoin

    go.drugbank.com/drugs/DB01320
    ApprovedInvestigational

    Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. … Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials.

    Categories: Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index
  8. Drug

    Acetohydroxamic acid

    go.drugbank.com/drugs/DB00551
    ApprovedInvestigational

    Acetohydroxamic Acid, a synthetic drug derived from hydroxylamine and ethyl acetate, is similar in structure to urea. In the urine, it acts as an antagonist of the bacterial enzyme urease.

  9. Drug

    Aztreonam

    go.drugbank.com/drugs/DB00355
    ApprovedInvestigational

    A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. … It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.

    Products: AZBIOS® 1G POLVO PARA RECONSTITUIR A SOLUCION INYECTABLE, AZTREONAM 1G POLVO PARA RECONSTITUIR A SOLUCIÓN INYECTABLE
  10. Drug

    Bucetin

    go.drugbank.com/drugs/DB13278
    ApprovedWithdrawn

    Bucetin is an analgesic and antipyretic medication which was approved for use in Germany but was withdrawn from the market in 1986 due to renal toxicity caused by the medication.[A175636]